(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of 3.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Arcus Biosciences's revenue in 2024 is $117,000,000.On average, 4 Wall Street analysts forecast RCUS's revenue for 2024 to be $16,332,953,013, with the lowest RCUS revenue forecast at $9,086,482,900, and the highest RCUS revenue forecast at $32,257,014,295. On average, 4 Wall Street analysts forecast RCUS's revenue for 2025 to be $11,607,981,905, with the lowest RCUS revenue forecast at $9,086,482,900, and the highest RCUS revenue forecast at $18,354,695,458.
In 2026, RCUS is forecast to generate $13,023,928,535 in revenue, with the lowest revenue forecast at $9,086,482,900 and the highest revenue forecast at $15,810,480,246.